NCT07011771

A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease

A Phase 1/2 Dose-Escalation Trial to Evaluate Safety, Tolerability, and Efficacy of a Single Dose of CAP-003 Gene Therapy Administered to Patients With Parkinson's Disease With GBA1 Gene Mutation (PD-GBA)

• Status: Suspended
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 31 (estimated)
• Sponsor: Capsida Biotherapeutics, Inc. · Industry
• Sex: All
• Age: 21 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn about the safety of CAP-003 gene therapy in adults with GBA1 associated Parkinson's Disease. It will also provide information about whether CAP-003 demonstrates efficacy in these adults. Participants will have a single intravenous infusion of CAP-003 and visit the clinic regularly for 2 years for checkups and tests.

Detailed description

This is a Phase 1/2, first-in-human, open-label, multi-centre, dose escalation trial to assess the safety, tolerability, and efficacy of a single intravenous (IV) dose of CAP-003 administered to adult patients aged 21 to 75 with Parkinson's Disease associated with GBA1 mutation. Approximately 31 participants will be dosed in this trial. Phase 1 is a dose escalation phase that will dose approximately 6 participants divided into 2 cohorts (Cohort 1 and Cohort 2) while Phase 2 will have 1 dose cohort and dose approximately 25 participants. Participants in Phase 1 will be dosed sequentially in each cohort. Phase 2 will allow participants to be dosed concurrently if safety and tolerability data from Phase 1 are deemed acceptable. Participants will receive a single IV infusion of CAP-003 and will then be followed for 2 years with safety measures, assessments to measure changes from Baseline in motor and non-motor scales, cognitive function, patient and clinical global impression of severity and improvement, disease progression, sleep scale and suicide severity rating. Upon completion of the study or at the participant's final visit they will be invited to participate in a 3 year safety follow up study.

Conditions

• GBA1 Parkinson Disease

Interventions

Type	Name	Description
DRUG	gene therapy	IV gene therapy
DRUG	gene therapy	IV gene therapy

Timeline

• Start date: 2025-08-18
• Primary completion: 2029-09-01
• Completion: 2029-11-01
• First posted: 2025-06-10
• Last updated: 2025-10-08

Locations

6 sites across 1 country: United States

Regulatory

• FDA-regulated drug study